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Abstract
IMPORTANCE—Despite concern about an “epidemic,” there are limited data on trends in 
prevalence of either type 1 or type 2 diabetes across US race and ethnic groups.
OBJECTIVE—To estimate changes in the prevalence of type 1 and type 2 diabetes in US youth, 
by sex, age, and race/ethnicity between 2001 and 2009.
DESIGN, SETTING, AND PARTICIPANTS—Case patients were ascertained in 4 geographic 
areas and 1 managed health care plan. The study population was determined by the 2001 and 2009 
bridged-race intercensal population estimates for geographic sites and membership counts for the 
health plan.
MAIN OUTCOMES AND MEASURES—Prevalence (per 1000) of physician-diagnosed type 1 
diabetes in youth aged 0 through 19 years and type 2 diabetes in youth aged 10 through 19 years.
RESULTS—In 2001, 4958 of 3.3 million youth were diagnosed with type 1 diabetes for a 
prevalence of 1.48 per 1000 (95% CI, 1.44–1.52). In 2009, 6666 of 3.4 million youth were 
diagnosed with type 1 diabetes for a prevalence of 1.93 per 1000 (95% CI, 1.88–1.97). In 2009, 
the highest prevalence of type 1 diabetes was 2.55 per 1000 among white youth (95% CI, 2.48–
2.62) and the lowest was 0.35 per 1000 in American Indian youth (95% CI, 0.26–0.47) and type 1 
diabetes increased between 2001 and 2009 in all sex, age, and race/ethnic subgroups except for 
those with the lowest prevalence (age 0–4 years and American Indians). Adjusted for 
completeness of ascertainment, there was a 21.1% (95% CI, 15.6%–27.0%) increase in type 1 
diabetes over 8 years. In 2001, 588 of 1.7 million youth were diagnosed with type 2 diabetes for a 
prevalence of 0.34 per 1000 (95% CI, 0.31–0.37). In 2009, 819 of 1.8 million were diagnosed with 
type 2 diabetes for a prevalence of 0.46 per 1000 (95% CI, 0.43–0.49). In 2009, the prevalence of 
type 2 diabetes was 1.20 per 1000 among American Indian youth (95% CI, 0.96–1.51); 1.06 per 
1000 among black youth (95% CI, 0.93–1.22); 0.79 per 1000 among Hispanic youth (95% CI, 
0.70–0.88); and 0.17 per 1000 among white youth (95% CI, 0.15–0.20). Significant increases 
occurred between 2001 and 2009 in both sexes, all age-groups, and in white, Hispanic, and black 
youth, with no significant changes for Asian Pacific Islanders and American Indians. Adjusted for 
completeness of ascertainment, there was a 30.5% (95% CI, 17.3%–45.1%) overall increase in 
type 2 diabetes.
CONCLUSIONS AND RELEVANCE—Between 2001 and 2009 in 5 areas of the United States, 
the prevalence of both type 1 and type 2 diabetes among children and adolescents increased. 
Further studies are required to determine the causes of these increases.
Information on recent trends in the prevalence of type 1 and type 2 diabetes in the United 
States is limited. Imperatore et al1 reported that the predicted increase in the number of 
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youth living with type 1 and type 2 diabetes by the year 2050 would be primarily among 
youth of minority race/ethnic groups. Worldwide, from 1990 to 2008, the incidence of type 
1 diabetes has been increasing by 2.8% to 4.0% per year,2 similar to that observed in the 
United States3 for both non-Hispanic white (hereafter called white) and Hispanic youth. 
However, a recent report from Finland, with the world’s highest incidence, suggested a 
possible leveling off of the increase from 2005–2011.4 Due to the very low mortality among 
youth with type 1 diabetes in the United States,5 an increase in the incidence of type 1 
diabetes will likely result in an increase in prevalence.
Type 2 diabetes is increasingly diagnosed in youth and now accounts for 20% to 50% of 
new-onset diabetes case patients,6 disproportionately affecting minority race/ethnic 
groups.7–9 Although few longitudinal studies have been conducted, it has been suggested 
that the increase in type 2 diabetes in youth is a result of an increase in the frequency of 
obesity in pediatric populations.10 Obesity in youth has been increasing since the 1960s 
though recent data suggest a plateau.11
There are a limited number of population-based studies of youth-onset type 2 diabetes. Most 
have involved American Indians and Native Canadians and showed high prevalence.7,12,13 
Similarly, type 2 diabetes incidence rates rose among non-Hispanic black (hereafter called 
black), Hispanic, and white children with insulin-treated, non–type 1 diabetes from 1994 to 
2003.14
We explored whether overall prevalence of type 1 and type 2 diabetes among US youth 
changed from 200115 to 200913 and whether it changed by sex, age, and race/ethnicity. 
Understanding changes in prevalence according to population subgroups is important to 
inform clinicians about care that will be needed for the pediatric population living with 
diabetes and may provide direction for other studies designed to determine the causes of the 
observed changes.
Methods
A SEARCH description has been published16 as have previous prevalence13,15 and 
incidence results.17 We report herein on changes in prevalence estimates between 2001 and 
2009, the only years in which prevalence was assessed. Methods of case ascertainment and 
prevalence estimation were the same in the 2 periods, including a 22-month window of 
ascertainment. Data were collected from 5 centers located in California (Kaiser Permanente 
Southern California, excluding San Diego [7 counties]), Colorado [14 counties, including 
Denver], Ohio [8 counties, including Cincinnati], South Carolina [4 counties, including 
Columbia], and Washington state [5 counties, including Seattle])15 as well as data from 
selected American Indian reservations in Arizona and New Mexico. The study was approved 
by the institutional review board (IRB) at each center. Because we attempted to identify 
100% of case patients, identification was conducted with an approved Health Insurance 
Portability and Accountability Act waiver of consent. Active surveillance used networks of 
pediatric and adult endocrinologists and other clinicians, hospitals, and health plans in the 
study areas. Case patients identified by International Classification of Diseases, Ninth 
Revision, were validated by verifying the diagnosis of diabetes with a physician to remove 
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miscoded case patients. Duplicated case patients were removed using combinations of name 
or initials (depending on IRB approval), date of birth, date of diagnosis, sex, and race/
ethnicity. After eligibility was verified based on residence and age, the case patient was 
registered with the coordinating center. Diabetes type diagnosed as type 1, type 1a, or type 
1b by the clinician was considered type 1 diabetes and diabetes diagnosed as type 2 was 
included as type 2 diabetes. All other types, including secondary forms, were excluded for 
this analysis (165 patients in 2001 and 191 in 2009).
Study Population
Case patients included all youth younger than 20 years who had been diagnosed with 
nongestational diabetes and who were prevalent in 2001 and 2009 on December 31 in 2001 
and 2009 and who resided in the geographic study area or were members of the participating 
health plans. Active duty military personnel or those who were institutionalized were not 
eligible. Race/ethnicity was based on self-report or medical records and on geocoding (ie, 
assignment of a US Census 2010 data–derived race/ethnicity proportion) for the youth who 
had missing data (4.2% in 2001 and 2.6% in 2009). We report type 2 diabetes prevalence 
only for those aged 10 through 19 years because there were not enough children younger 
than 10 years to establish stable rates (5 in 2001; 19 in 2009).
The study population included youth younger than 20 years residing in the geographic study 
areas or who were members of participating health plans in 2001 and 2009. For the 
geographically based sites, the population was defined by the 2001 and 2009 bridged-race 
intercensal population estimates.18 For California, addresses were geocoded to the census-
block level and the race/ethnic–specific proportions were applied to estimate the racial and 
ethnic composition of youth by age and sex. Patients of the Indian Health Service for the 
preceding 3 years determined the American Indian study population. Estimates were then 
pooled across all 5 sites. Race/ethnic categories included: Hispanic, white, black, Asian 
Pacific Islanders, and American Indians and were determined by first identifying any 
residents of Hispanic ethnicity and then by applying race-bridging methods18 to multiracial 
youth to ascertain the probability of belonging to each of the 4 other racial groups. The study 
population of those aged 17 through 19 years had counts of active duty military personal 
removed.
Data Collection
Demographic information, date of diagnosis, and diabetes type were obtained from medical 
records. We validated clinician diagnoses of diabetes type through an etiologic assessment 
of diabetes type, defined as presence of at least 1 diabetes autoantibody (glutamic acid 
decarboxylase or insulinoma associated antibody) using harmonized assays19 for type 1 
diabetes and in the absence of diabetes autoantibodies and in the presence of insulin 
resistance based on a clamp validated index20 for type 2 diabetes. This information came 
from an in-person research visit available on youth who had provided written informed 
consent or assent. Because no visits were made to patients at the time of diagnosis in the 
years 2001 and 2009, data from the 2 closest incident years (2002, 2008) were used. Patients 
with diabetes onset in 2002 or 2008 were identified using the same methods as those in 2001 
and 2009. To assess generalizability, selected demographic characteristics of the SEARCH 
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study population were compared with the US population using US Census 2000 and 2010 
summary files.
Statistical Analyses
Prevalence was expressed as cases of type 1 or 2 diabetes per 1000 youth pooled across all 
sites with 95% CIs. Statistical tests for trends used a 2-sided skew-corrected inverted score 
test assuming a binomial distribution.21 Assuming a significance level of 5%, we had more 
than 90% power to detect a change in prevalence of 0.07 per 1000 youth for the overall 
population and of 0.12 per 1000 youth for subgroup analyses. To assess trends over time it is 
important to determine whether case patients were identified with the same completeness of 
ascertainment in both years. This was estimated for the 4 geographic-based sites using the 
capture-recapture method.22 For each center, case patients were identified from multiple 
sources (from 13 to 41). A source was defined as any location from which case patients were 
reported. Matching across sources to identify potential duplicate records was performed at 
the center level using personal health identifiers. Once matching was accomplished, the 
sources were further grouped into 2 modes of ascertainment (clinicians and inpatient 
hospital system records). Using the number of duplicate and case patients unique to one or 
the other source allowed calculation of the total estimated case patients in the geographic 
region.22 The percentage completeness of ascertainment for each site was taken as the 
number of observed case patients divided by the total estimated number from the capture-
recapture method. Pooled estimates used a global logarithmic-linear model and maximum 
likelihood analysis23 using SAS version 9.3 (SAS Institute Inc). The 95% CIs computed for 
the capture-recapture adjusted prevalence estimates account for the variation in the 
estimates. Approximately 20% of the study population was ascertained in membership-
based sites where it was impossible to assess completeness of ascertainment using capture-
recapture analyses due to the lack of independent sources of case patient ascertainment.
Results
Type 1 Diabetes
In 2001, 4958 patients with type 1 diabetes were identified from a population of 3 345 783; 
the respective case patients and population were 6666 and 3 458 974 in 2009 (Table 1). 
Prevalence was 1.48 per 1000 (95% CI, 1.44–1.52) in 2001 and 1.93 per 1000 (95% CI, 
1.88–1.97) in 2009, representing an increase of 30.0% (95% CI, 25.4%–34.9%) over the 8-
year period. Statistically significant increases were observed within each age, race/ethnic, 
and sex subgroup evaluated except for youth age 0 through 4 years and American Indians, 
which were the 2 population subgroups with the lowest prevalence of type 1 diabetes in 
2001 and 2009. The greatest prevalence increase was observed in those aged 15 through 19 
years.
Type 2 Diabetes
Table 2 shows the prevalence of type 2 diabetes for 2001 and 2009 among youth aged 10 to 
19 years. In 2001, 588 of 1 725 846 and in 2009, 819 of 1 781 260 had type 2 diabetes. The 
overall prevalence was 0.34 per 1000 (95% CI, 0.31–0.37) in 2001 and 0.46 per 1000 (95% 
CI, 0.43–0.49) in 2009, representing a relative increase of 35% (95% CI, 21.4%–50.0%). A 
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statistically significant increase was seen in both sexes, in those aged 10 through 14 years 
and 15 through 19 years, and in white, black, and Hispanic youth. No significant changes 
were seen in Asian Pacific Islander or American Indian youth. The prevalence of type 2 
diabetes was higher in both periods among those aged 15 through 19 years than among those 
aged 10 through 14 years and higher among females than among males; larger absolute 
increases were seen in these groups over time (P < .001, Table 2).
Completeness of Case Ascertainment
The overall completeness for type 1 diabetes was estimated to be 92.5% (95% CI, 91.8%–
93.3%) in 2001 and 99.3% (95% CI, 99.2%–99.5%) in 2009. For type 2 diabetes it was 
estimated to be 92.9% (95% CI, 90.6%–95.2%) in 2001 and 96.1% (95% CI, 94.6%–97.6%) 
in 2009 (Table 3). After adjustment for completeness of ascertainment, type 1 diabetes 
prevalence for 2001 was 1.60 per 1000 (95% CI, 1.54–1.67) and for 2009 was 1.94 per 1000 
(95% CI, 1.89–2.00), representing an adjusted increase of 21.1% (95% CI, 15.6%–27.0%). 
After adjustment for completeness of ascertainment, type 2 diabetes prevalence for 2001 
was 0.37 per 1000 (95% CI, 0.34–0.40) and in 2009 it was 0.48 per 1000 (95% CI, 0.45–
0.51), representing an adjusted increase of 30.5% (95% CI, 17.3%–45.1%).
Etiologic Criteria
We also explored whether similar proportions of case patients diagnosed by clinicians with 
type 1 or type 2 diabetes in the 2 years met etiologic criteria for diabetes type.20 Among 
those with type 1 diabetes, 84.2% had positive antibodies in 2002 and 85.7%, in 2008 (P = .
50; Table 4). Among those with type 2 diabetes, 82.1% in 2001 and 88.7% in 2009 (P = .23) 
met the etiologic criteria. Similar small differences by age group and by race/ethnicity did 
not reach statistical significance, except for white youth with type 2 diabetes: 55.6% in 2002 
and 90.9% in 2008 met etiologic criteria (P = .01). Except for this subgroup, trends in the 
accuracy of diagnosis of diabetes type were stable over time.
Representativeness of the SEARCH Population
Table 5 shows that for race/ethnicity, age, parental educational attainment, and median 
household income, the proportional distribution for 2001 and 2009 was very similar to the 
US census for 2000 and 2010. Thus, we were satisfied that the study areas reasonably 
represented the US population.
Discussion
Type 1 Diabetes
Over the 8-year period, the adjusted prevalence of type 1 diabetes increased 21.1% (95% CI, 
15.6%–27.0%) among US youth. Increases were observed in both sexes; in white, black, 
Hispanic, and Asian Pacific Islander youth; and in those aged 5 years or older. Historically, 
type 1 diabetes has been considered a disease that affects primarily white youth; however, 
our findings highlight the increasing burden of type 1 diabetes experienced by youth of 
minority racial/ethnic groups as well.
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Increases in the prevalence of type 1 diabetes could reflect increases in disease incidence, 
decreases in mortality, or both. Mortality due to diabetes in youth is low (1.05 per million 
for aged ≤19 years in 2008–20095); therefore, an increase in type 1 diabetes incidence is the 
most likely primary explanation. Increases in the incidence of type 1 diabetes have been 
observed around the world,24 and more recently, increases among white, Hispanic, and 
black youth in the United States have been reported.3,25 A doubling of incidence rates from 
1978 to 2007 was reported in Sweden,26 although declining cumulative incidence was 
observed in the 2000–2006 birth cohorts. Similarly, a Finnish report showed that even 
though the incidence increased from 1989 to 2005, no further increase in incidence of type 1 
diabetes occurred between 2005 and 2011.4
Through the year 2000, published prevalence estimates from around the world ranged from 
0.03 to 1.83 per 1000,27,28 whereas after 2000, estimated prevalence ranged from 0.06 to 4.8 
per 100015,29,30 compared with our estimate of 1.93 per 1000 in 2009. Overall prevalence of 
type 1 diabetes was 1.58 per 1000 in Philadelphia schools, somewhat lower than our 
estimates, and race/ethnic specific differences were all lower than what we found: 0.73 per 
1000 among white, 0.56 among black, and 0.50 among Hispanic youth.29 These estimates 
are difficult to compare because of differences in ascertainment methods, race/ethnicity, and 
age composition of the populations across studies. Few studies have projected changes in 
prevalence of type 1 diabetes among contemporary youth. Based on SEARCH data, 
Imperatore et al1 modeled the number of youth who would have type 1 diabetes in 2010 and 
2050, which was estimated to nearly triple, from 179 387 in 2010 to 587 477 in 2050, due to 
large increases in the numbers of minority race/ ethnic groups. The increase in prevalence 
among US minorities documented herein is of concern, given that minority youth are more 
likely to have poor glycemic control,31 known to be associated with the serious 
complications of type 1 diabetes.
Type 2 Diabetes
We also report, to our knowledge, the only multiethnic data on changes in the prevalence of 
type 2 diabetes in youth. The prevalence of type 2 diabetes in 2009 among adolescents aged 
10 through 19 years was 0.46 per 1000 or 0.046%, with highest prevalence in American 
Indians, followed by black, Hispanic, and Asian Pacific Islander youth, with lowest 
prevalence in white youth, a pattern that is almost the inverse of that seen in type 1 diabetes. 
Prevalence was somewhat lower than reported in fifth- to 12th-grade students in Ohio 
(0.08%, previously diagnosed type 2 diabetes),32 although a higher proportion of black 
students were included in that study. It was also lower than the screening results in the 
Studies to Treat or Prevent Pediatric Type 2 Diabetes33 (STOPP-T2D) involving eighth-
grade students, which documented a 0.5% prevalence of elevated screening glucose levels; 
however, only a single screening test was used. Compared with our estimate of 0.46 per 
1000, the reported prevalence among sixth graders in the HEALTHY study (0.2 per 1000)34 
was lower, as was prevalence among students in the Philadelphia schools (0.35 per 1000 
overall29), which also reported substantially lower race/ethnicity specific estimates (0.03 per 
1000 white; 0.28 per 1000 black; and 0.05 per 1000 Hispanic youth).
Dabelea et al. Page 7













We showed that the overall prevalence of type 2 diabetes between 2001 and 2009 increased 
by 30.5% when adjusted for differences in completeness of ascertainment. Increases 
occurred in white, Hispanic, and black youth, whereas no changes were found in Asian 
Pacific Islander and American Indian youth. Projections suggest that the number of youth 
with type 2 diabetes will increase from 22 820 in 2010 to 84 131 in 2050, a 4-fold increase.1 
Our data also suggest that there was little change in the pattern of diagnosis of diabetes type 
that clinicians used over this period, with the exception of white youth. We can only 
speculate about whether changes in the awareness of type 2 diabetes in youth over time may 
have accounted for this change. Because a lower proportion of white youth met the etiologic 
criteria in the first period, the rates for 2001 may have been overestimated, and therefore we 
may have underestimated the increase in type 2 diabetes among white youth.
There are limited population-based data on temporal trends of type 2 diabetes in youth. In 
Cincinnati, Ohio, type 2 diabetes incidence increased 10-fold, from 1982 to 1994 (average 
annual change, 41.7%).35 Annual incidence rates from 1994 to 2003 increased by 3.7% 
among white, 3.9% among black, and 9.6% among Hispanic children with insulin-treated, 
non–type 1 diabetes in Chicago14; however, these case patients represent an unknown 
proportion of all case patients. Among aboriginal youth in Alberta, Canada,12 a 14% average 
annual increase was reported in Chicago between 1995 and 2007 in youth younger than 20 
years. Dabelea et al7 showed an increase in prevalence of type 2 diabetes in Pima Indian 
youth aged 10 through 19 years in both sexes, with the highest prevalence in females. In 
Pima, the estimated average annual increase ranged from 1.9% to 10%, whereas we 
estimated the average annual increase at 4.4% overall, similar to that seen among the Pima 
Indians.
Studies in Europe36,37 indicate that type 2 diabetes remains rare in largely white 
populations, and 1 report showed no trend38; however, we observed a significant prevalence 
increase in white youth. Although differences in obesity rates between US and European 
youth are likely contributors, the full explanation for these discrepancies deserves further 
study.
Several reasons for the increasing type 2 diabetes prevalence are possible. Most likely are 
real changes in population risk for type 2 diabetes, such as minority population growth, 
obesity, exposure to diabetes in utero,39 and perhaps endocrine-disrupting chemicals.40 
Similarly, changing awareness of type 2 diabetes in youth leading to different diagnostic 
practices may have contributed to the increases.
Our study has limitations and strengths. We only included youth with diagnosed diabetes, 
which will miss youth who may meet diagnostic criteria for type 2 diabetes if screened, 
although this is much less of a limitation for youth with type 1 diabetes. However, the 
number of undiagnosed cases of type 2 diabetes is likely to be small.32,34 We only included 
2 years of data and rates may vary from year to year. Also, the last year of data was 2009, 5 
years ago, so we are not able to comment on whether current prevalence has changed. There 
were relatively small numbers of youth in some groups by race/ethnicity (especially 
American Indian and Asian Pacific Islanders) making these estimates of changes in 
prevalence less precise. Our observation period was relatively short and further surveillance 
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will produce better estimates of changes. Strengths of the study include large numbers of 
youth identified using consistent methods from 2 periods; the population-based nature of the 
study; the racial/ethnic composition of the populations, which was similar in distribution to 
the United States; and the ability to show that our findings were not overly influenced by 
changes in case ascertainment or in clinician’s diagnostic patterns of diabetes type.
The increases in prevalence reported herein are important because such youth with diabetes 
will enter adulthood with several years of disease duration, difficulty in treatment,41 an 
increased risk of early complications, and increased frequency of diabetes during 
reproductive years, which may further increase diabetes in the next generation.7
Conclusions
Between 2001 and 2009 in 5 areas of the United States, there was an increase in the 
prevalence of both type 1 and type 2 diabetes among children and adolescents. Further 
studies are required to determine the causes of these increases.
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Table 3
Estimated Completeness of Case Ascertainment for Youth With Diabetes Using Capture-Recapture for 4 
Geographic Sites Combined, by Year, Age Group, Sex, and Race/Ethnicity
Diabetes
% Completeness (95% CI)
2001 2009
Overall
 Type 1 92.5 (91.8–93.3) 99.3 (99.2–99.5)
 Type 2 92.9 (90.6–95.2) 96.1 (94.6–97.6)
Age, y
 Type 1
  0-≤4 93.7 (92.9–94.6) 99.6 (99.6–99.7)
  5-≤9 93 (92.5–93.4) 99.5 (99.5–99.6)
 10-≤14
  Type 1 93.2 (92.8–93.5) 99.4 (99.4–99.4)
  Type 2 96 (95.2–96.8) 96.8 (96.4–97.2)
 15-≤19
  Type 1 91.7 (91.3–92) 96.5 (96.2–96.8)
  Type 2 91.7 (90.9–92.6) 94.6 (93.8–95.5)
Sex
 Female
  Type 1 93.1 (92.8–93.3) 99.4 (99.3–99.4)
  Type 2 94 (93.3–94.7) 96.8 (96.4–97.1)
 Male
  Type 1 92 (91.7–92.3) 99.3 (99.3–99.3)
  Type 2 90.8 (89.4–92.2) 94.3 (93.4–95.3)
Race/ethnicity
 White
  Type 1 93.1 (92.8–93.3) 99.4 (99.4–99.4)
  Type 2 92.2 (91–93.4) 97 (96.5–97.5)
 Black
  Type 1 96.6 (96.3–97) 99.7 (99.7–99.8)
  Type 2 96.5 (95.9–97) 98.8 (98.5–99)
 Hispanic
  Type 1 91.9 (90.9–92.8) 98.9 (98.8–99)
  Type 2 82.8 (77.8–87.7) 90 (88–92)
 Othera
  Type 1 85.8 (83.8–87.9) 99.2 (99–99.3)
  Type 2 91 (87.7–94.4) 94.4 (92.5–96.3)
a
Other includes Asian/Pacific Islanders, American Indian, and other race/ethnicity.
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Table 5




SEARCH 2001 Prevalence 
Populationa US Census 2010
SEARCH 2009 Prevalence 
Populationb
Race/ethnicityc
 White 194 552 774 (69.1) 7 638 429 (64.9) 196 817 552 (63.8) 7 689 947 (61.0)
 Black 33 947 837 (12.1) 977 677 (8.3) 37 685 848 (12.2) 1 051 643 (8.3)
 Hispanic 35 305 818 (12.6) 1 916 968 (16.3) 50 477 594 (16.4) 2 340 785 (18.6)
 American Indian 2 068 883 (0.7) 248 343 (2.1) 2 247 098 (0.7) 238 507 (1.9)
 Asian Pacific Islander 10 476 678 (3.7) 701 027 (6.0) 14 946 700 (4.8) 934 989 (7.4)
 Non-Hispanic: some other race 467 770 (0.2) 20 885 (0.2) 604 265 (0.2) 23 256 (0.2)
 Non-Hispanic: ≥2 races 4 602 146 (1.6) 263 063 (2.2) 5 966 481 (1.9) 336 406 (2.7)
Age, yc
 0-≤4 19 175 798 (6.8) 837 430 (7.1) 20 201 362 (6.5) 852 042 (5.3)
 5-≤9 20 549 505 (7.3) 895 283 (7.6) 20 348 657 (6.6) 847 743 (5.3)
 10-≤14 20 528 072 (7.3) 880 014 (7.5) 20 677 194 (6.7) 849 263 (5.3)
 15-≤19 20 219 890 (7.2) 842 557 (7.2) 22 040 343 (7.1) 891 970 (5.6)
Education, for adults ≥25 yd
<High school graduate (19.6) (16.9) (14.9) (13.0)
 High school graduate (28.6) (23.6) (29.0) (23.9)
 Some college (27.4) (30.2) (28.1) (29.7)
≥Bachelor’s degree (24.4) (29.3) (27.9) (33.4)
Median household income, US $d 41 994 43 649 51 914 60 129
a
Data are from 2000, but the prevalence areas were defined by SEARCH in 2001.
b
Data are from 2010, but the prevalence areas were defined by SEARCH in 2009.
c
Data are from Summary File 1 from the 2000 and 2010 Census.
d
Data are from Summary File 3 from the 2000 Census and data are based on 5-y estimates from 2010 American Community Survey. SEARCH 
prevalence population numbers do not include American Indian subsite information for Education and Income.
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